Index

Page numbers in *italics* refer to figures; those in **bold** refer to tables.

- Absolute Risk Reduction (ARR) 162
- Accelerated Approval 324
- Accelerated Assessment 325
- accelerator mass spectrometry (AMS) 192
- action potential 184, 184
- duration (APD) prolongation 121, 122, 184
- active pharmaceutical ingredient (API) 27
- chiral active ingredients 206–9, 277
- stereochemical purity 106, 269, 270
- environmental impact 290
- formulation 94–9
- enteral formulations 95–6
- parenteral formulations 96
- poorly soluble drugs 97–9
- new forms of 343
- physicochemical characterisation 92–4
- pre-approval development 255–6
- quality determination 99–106
- chromatography 103–5
- melting point 105
- spectrometry 100–103
- quality specifications 178–9, 202, 257–69
- Critical Quality Attributes (CQAs) 206
- enantiomer specification 269, 270
- impurity profiling and reporting 257–64
- microbial purity 267–9, 269
- particle size 266, 267
- polymorphic modifications 266–7, 268, 272–3, 274
- residual solvent 265–6
- stability testing 211, 211–12
- **see also** Environmental Risk Assessment (ERA)
- Active Substance Master File (ASMF) 56–7, 57
- acute toxicology studies 125–6, 186
- adaptive study designs 152–3, 234
- Multiple Ascending Dose (MAD) study 240–241
- ADME (absorption, distribution, metabolism and excretion) 31, 107
- Adverse Drug Reactions (ADR) 236, 338, 340–341
- reporting 339
- Adverse Events (AE), First-In-Human (FIH) study 236
- advertising
  - Direct To Consumer (DTC) 380, 381
  - medical journals 378
- ALARP approach 79, 265
- allometric scaling 20, 198, 200
- Ames test 18, 126–7, 188, 221
- analytical development 30, 176–7
- animal experimentation 81–3
- anti-depressants 303
- anti-diabetic drugs, cardiovascular risk assessment 308–10, 309
- apparatus 64
- assay development 17
- assay sensitivity 160
- atmospheric-pressure chemical ionisation (APCI) 101
attrition rates 7–8
audits 72

benefit-risk assessment 314–15, 347
Periodic Benefit-Risk Evaluation Reports (PBRER) 345–6
Best-in-Class drug 249
Best Pharmaceuticals for Children Act (BPCA), US 356
bias 160
bilirubin 218
bioactivation 112
bioanalysis 117
bioassay development 17
bioconcentration factor (BCF) 294
biodegradation 111–12
bioequivalence (BE) trials 153, 216
biomarkers 140–141, 247
personalised treatment development 344–5
biopharmaceutical classification system (BCS) 172–3, 173
blinding 150
bovine corneal opacity and permeability test (BCOP) 20–21, 81, 128, 189
Breakthrough Therapy 324–5
bridging study 310
British National Formulary (BNF) 382, 383
Budget Impact Analysis (BIA) 368
buffers 97
buildings, requirements of 62
business risks 77
Caco-2 permeability assay 19, 107–8, 182
carcinogenicity
mechanisms 284–5
testing 136, 138, 221, 284–8
dose selection 285–6
interpretation 286–9
post-approval studies 329–31
cardiac stress test 147
cardiovascular safety studies 119–24, 184–6, 197, 244
anaesthetised animals 123, 185
anti-diabetic drugs 308–10, 309
conscious telemetered dog assay 123–4
hERG binding assay 119–20, 185
hERG patch clamp assay 120, 120–121, 185
isolated rabbit heart assay 121–3, 185
pre-approval studies 306–10
Purkinje fibre assay 121, 122, 185
QT interval prolongation 184–5, 244, 306–8
case-control studies 149, 155, 156, 341
Case Report Forms (CRF) 68
case reports 149, 155
case series 149, 155
cash flow during drug life cycle 361–2, 362
Centre for Drug Evaluation and Research (CDER), US 46, 53, 316–17
Centre for Innovation in Regulatory Science (CIRS), UK 314
Certificate of the European Pharmacopoeia (CEP) 57–8
chemical ionisation (CI) 101
carcinogenicity mechanisms 284–5
testing 136, 138, 221, 284–8
dose selection 285–6
interpretation 286–9
post-approval studies 329–31

see also genotoxicity
clinical development 33–5, 139–66
biomarkers 140–141, 142
clinical phase studies 226–50
phase 2a studies 245–50
phase 1 studies 227–45
clinical trial methodology 147–63
organisational challenges 163–6
human electrocardiography (ECG) 146, 146–7
imaging techniques 142–5
pharmacometrics 139–40
planning for 193–6
clinical development plan preparation 193–4
First-In-Human (FIH) study preparation 194–6
risk assessment of drug candidate 193
post-approval studies 333–45
Comparative Effectiveness Research (CER) 336–8
effectiveness vs. efficacy 334–6
new developments 342–5
pharmacovigilance 338–42
phase 4 studies 333–4
pre-approval studies 297–311
end-of-phase 2 meeting 299–300
phase 2b studies 297–9
phase 3 studies 300–311
pre-clinical phase studies 190–196
see also clinical phase of development
clinical equivalence (CE) trials 153
clinical phase of development 200–251
chemical and pharmaceutical development 201–15
chiral active ingredients 206–9
container closure system 213–14
INDEX

formulation development for clinical phase 2 209, 209–10
manufacturing process development 203–6, 207, 210
new synthesis method 201–2
Quality by Design (QbD) approach 214–15
stability testing 210–13
clinical development 226–50
phase 2a studies 245–50
phase 1 studies 227–45
integration and decision making 250–251
nonclinical development 215–26
pharmacokinetics 216–19
toxicology 219–26
see also clinical development
clinical practice guidelines 269
Clinical Research Associates (CRA) 71
Clinical Study Monitors (CSM) 71
Clinical Trial Authorisation (CTA) application 51, 52
clinical trials 33–5, 36, 37, 147–63
combining clinical evidence 160–162
hierarchy of evidence 149, 149
modelling 140
observational studies 149, 154–7
organisational challenges 163–6
payments to participants 87, 228
protocol 69
randomised controlled trial (RCT) 149–54
reporting of results 162–3
statistical analysis issues 159–60
study endpoints 157–9, 302
study validity 160
types of 138–9
see also First-In-Human (FIH) clinical trial;
phase 2a studies; phase 2b studies; phase 1 studies; phase 3 studies; phase 4 studies
CNS safety 124
Cochrane collaboration 162
cohort studies 149, 156–7, 157
co-marketing 377
combination therapies 343–4
commercialisation 362–3
drug pricing 363–4
drug reimbursement 364–9
market access 327–8, 363
see also pharmaceutical marketing
commitment studies 333
Committee for Human Medicinal Products (CHMP) 45, 319–20
Accelerated Assessment 325
Committee for Orphan Medicinal Products (COMP) 352
Common Technical Document (CTD) 44, 315
Comparative Efficacy Research (CER) 303–4
Comparative Effectiveness Research (CER) 304, 334, 336–8, 337
compassionate use programme, Europe 326–7
compatibility testing 94
complaints 62–3
composite endpoints 158
computed tomography (CT) 143
Conditional Marketing Authorisation 325
confidentiality 80, 87
conflicts of interest 80
confounding 160
conscious telemetered dog assay 123–4
CONSORT (CONsolidated Standards Of Reporting Trials) 163
container closure system 213–14
continuous medical education (CME) 379
contract production 62
controlled clinical trials 148
co-promotion 377
Core Value Dossier (CVD) 347
Corrective Actions and Preventive Actions (CAPAs) 71
cost analysis 366
cost effectiveness 366, 377
Cost Benefit Analysis (CBA) 367
Cost Efficacy Analysis (CEA) 335, 366–8, 368
Cost Minimisation Analysis (CMA) 366
costs of drug development 6–7
estimates 7
Cost Utility Analysis (CUA) 366–7
Coverage with Evidence Development (CED) 369
Critical Process Parameter (CPP) 215
Critical Quality Attributes (CQAs) 206, 215
crossover study design 151, 152
cross-sectional studies 148, 149, 155
customised targeting 377
cytochrome P450 enzymes 112–13, 220
isoform determination 115, 115
cytotoxic anti-cancer drugs 228
Data Monitoring Committee (DMC) 68
Data Safety and Monitoring Board (DSMB) 68
Declaration of Helsinki 83, 84
decomposition studies 94
degradation 270–272
active ingredient 270
biodegradation 111–12
degradant reporting 271–2, 272, 273
degradant specification 270–271, 271
drug product 271–2
see also stability testing
depression 302, 303
dimethylsulfoxide 97
Direct To Consumer (DTC) advertising 380, 381
INDEX

disease management 378
disease models 140
disintegration time 96
dissolution, drug product 273–7, 275–7
documentation 62, 65–6
dose selection 297–9
carcinogenicity testing 285–6
geriatric drugs 357–8
paediatric drugs 355–6
clinical-trial-based 356
PK-based 355–6
safe starting dose calculation 199–200, 235
see also Multiple Ascending Dose (MAD) study; Single Ascending Dose (SAD) study
drug development
costs 6–7
estimates 7
failure and success rates 7–8
fixed-dose combinations 358–60
geriatric drugs 356–8
management 10
objective 23–4
organisations and teams 24–6, 26
orphan drugs 351–4, 354
paediatric drugs 354–6
phases 36–44
milestones 38–44, 39–42
see also specific phases
risks 7–9
streams 27–36, 28
chemical and pharmaceutical development 27–30
clinical development 33–5
interaction between 35–6
nonclinical development 31–2
drug discovery 13, 16–21, 17
assay development 17
exploratory phase 17
hit-to-lead 18–19
lead optimisation 19–21
molecular drug design 15–16
phenotypic-based approach 14
screening 18
search drivers for new drugs 2–5
operational criteria 4–5
scientific/technical criteria 3–4
strategic criteria 3
target-based approach 14–15
drug-drug interactions 219, 310–311
post-approval studies 330
pre-approval studies 283
drug life cycle 5–6, 6
cash flow during 361–2, 362
Drug Master Files (DMF) 56, 57
drug metabolism see metabolism
drug models 139–140
drug prescription formularies 370
drug pricing 363–4
drug product
pre-approval development 256–7
quality specifications 179–80, 181, 270–279
degradation 270–272, 271
in vitro dissolution 273–7, 275–7
microbial purity 277–9, 278
polymorphism 272–3, 274
stability testing 212–13
drug reimbursement 364–9
Drug Safety Research Unit (DSRU) 340
drug-device combinations 344
drug utilisation studies 341
dual-energy X-ray absorptiometry (DEXA) 145
eyearly drug development 36–8, 39–40, 169–70
clinical phase 200–251
pre-clinical phase 170–200
echocardiography 145
ecotoxicity see Environmental Risk Assessment (ERA)
effectiveness 335
Comparative Effectiveness Research (CER) 303, 334, 336–8, 337
versus efficacy 334–6
see also cost-effectiveness
efficacy 334
absolute efficacy 301–3
Comparative Efficacy Research (CER) 303–4
versus effectiveness 334–6
overall efficacy assessment 313–14
Preservative Efficacy Test (PET) 278, 279
relative efficacy 303–5
Comparative Efficacy Research (CER) 303–4
electrocardiography (ECG) 146, 146–7, 244
ambulatory 147
Electronic Healthcare Records (HER) 339
electron ionisation (EI) 101
electrospray ionisation (ESI) 101
embryo-fetal development studies 133–5, 134, 224, 288
emulsions 98–9
enantiomer specification setting 269, 270
end-of-phase 2 meeting 299–300
enteral formulations 95–6
Environmental Risk Assessment (ERA) 290–297
Europe 291–4
ERA Phase I 291, 291
ERA Phase II 292–4, 293, 295
reporting 294
US 294–7
reporting 296–7
tiered approach 294–5, 296
equivalence trials 153
ethical considerations 79–87
animal studies 81–3
confidentiality versus transparency 80–81
conflicts of interest 80
experiments involving human subjects 83–7, 84
confidentiality 87
ethics review of clinical research 84–5
historical background 83
informed consent 86
payments 87
placebo use 85–6
scientific research integrity 79–80
EudraCT database 52
EUnetHTA 338
European Medicines Agency (EMA) 24, 45–6, 318–20
Committee for Human Medicinal Products (CHMP) 45, 319–20
Committee for Orphan Medicinal Products (COMP) 352
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 342
European Pharmacopoeia 47–8
Certificate of (CEP) 57–8
eutectic formation 94
evergreening 345
Evidence Based Health Care (EBHC) 162
Evidence Based Medicine (EBM) 161–2, 336–7, 337
excipients 95, 173–5, 174
environmental impact 290
see also Environmental Risk Assessment (ERA)
GRAS excipients 173
incompatibility 173
excretion 110–111
First-In-Human (FIH) study 237
Exercise Tolerance Test (ETT) 298
expanded access, US 327
exploratory studies 190–192, 191
external risks 77
external validity 160
fast atom bombardment (FAB) 101
Fast Track Development procedure 324
definitions 171, 173
fertility studies 133, 134, 224, 288
First-in-Class drug 249
First-In-Human (FIH) clinical trial 43, 227, 231–9
dose escalation 235
drug administration 235–6
investigator site 232
pharmacodynamics 238–9
pharmacokinetics 237–8
preparation 194–6
safe starting dose calculation 199–200, 235
safety and tolerability 236–7
study design 232, 233–4
study population 232–3
first-in-patient studies 245
see also phase 2a studies
first-pass effect 112, 112
Fixed-Dose Combinations (FDC) 343–4
development of 358–60
fluorometry 100
Food and Drug Administration (FDA), US 24, 46, 317–18
Accelerated Approval 324
Breakthrough Therapy 324–5
Center for Drug Evaluation and Research (CDER) 46, 53, 316–17
Fast Track Development procedure 324
inspections 318
Office of Orphan Products Development (OOPD) 353
Priority Review 324
food impact on absorption 238
forced decomposition studies 94
formularies 382
formulation 94–9
development 171–6
degradation 176
excipients 173–5, 174
new formulations 343
phase 2b trials 256–7
phase 1 trials 175–6, 209
phase 2 trials 209, 209–10
phase 3 trials 256, 256–7
research 171–3
enteral formulations 95–6
parenteral formulations 96
poorly soluble drugs 97–9
tox formulations 175
fraud 80
Full Analysis Set (FAS) 159
functional magnetic resonance imaging (fMRI) 144
gas chromatography (GC) 102, 104
genotoxicity 197
testing 18, 19–20, 126–8
Ames test 18, 126–7, 188, 221
clinical phase studies 221–2
micronucleus assay 127–8, 188
mouse lymphoma assay 127, 188
pre-approval studies 284
pre-clinical phase studies 187–9
geriatric drug development 356–8
INDEX

396

good practices 59–70, 60

- Good Clinical Practices (GCP) 66–70
- Good Laboratory Practices (GLP) 63–6
- Good Manufacturing Practices (GMP) 60–63
- Good Pharmacovigilance Practices (GVP) 74, 341

Hazard Ratio (HR) 162

Health Technology Assessment (HTA) 337, 337, 347, 365

hen chorio-allantoic membrane test (HET-CAM) 20–21, 128–9, 189

hepatic insufficiency 310

hepatocellular tumours, rodent 287

hERG binding assay 20, 119–20, 185

hERG patch clamp 19, 120, 120–121, 185

high-performance liquid chromatography (HPLC) 104, 117

high-throughput screening (HTS) 18

Holter monitoring 147

Human Equivalent Dose (HED) derivation of 198, 199

Maximum Recommended Safe Starting Dose (MRSD) calculation from 199–200

imaging techniques 142–5
dual-energy X-ray absorptiometry (DEXA) 145

magnetic resonance imaging (MRI) 143–4

positron emission tomography (PET) 144–5

single-photon emission computed tomography (SPECT) 144–5

ultrasonography (US) 145

immunotoxicology 136–8, 225

impurities 257–66
elimination of 204

impurity profile 58, 202, 257–62

overview 257–9

mutagenic alerts 284

pharmaceutical evaluation 264–5

qualification 30, 260–261

quality specifications 257–62, 260, 262
degradant specification 270–271, 271

reporting 262–4, 264

residual solvent 265–6

specified impurities 261
during synthesis process 203–4, 204, 260, 260

IMS Health 371

Incremental Cost-Effectiveness Ratio (ICER) 366

independent drug information 382–3

Independent Drug Information Service (IDIS) 382

Independent Ethics Committee (IEC) 67, 84–5

Individual Case Safety Reports (ICSR) 339

informed consent 86

infrared (IR) spectrometry 100, 101

inspections 72–3

Institutional Review Board (IRB) 67, 84–5

instruments 62

intellectual property (IP) issues 29–30

Intention-To-Treat (ITT) study set 159

interlocking cohort study design 234, 234

internal validity 160

International Conference on Harmonisation (ICH) 46–7, 205

storage conditions 211, 211

interventional clinical trials 148

intravascular ultrasound (IVUS) 145

Investigational Medicinal Product Dossier (IMPD) 51, 52, 54, 281

Investigational New Drug (IND) application 46, 51, 53–4, 281
types of 53

investigator 67–8

Investigator-Initiated Trials (IITs) 334

Investigator’s Brochure (IB) 51, 52, 55, 69–70

Investigator Study File (ISF) 68

in vitro phototoxicity assay 129, 223

in vivo vascular tolerance assay 129–30

irrational use of medicines 383

isolated rabbit heart assay 121–3, 185

juvenile development studies 135, 137

juvenile toxicology 288–90, 329, 331

Key Opinion Leaders (KOL) 380

Langendorff perfused heart model 121

late drug development 38, 41–2, 253–4

marketing authorisation (MA) 316–28

post-approval development 328–47

pre-approval development 254–316

Latin square design 151, 152

launch of new drug 44

lead optimisation 19–21

legislation 44–5, see also regulation

liposomes 99

liquid chromatography (LC) 102, 104–5, 105, 106

liquid formulations 96

liquid scintillation counting (LSC) 116

liver enzyme induction and inhibition 115, 182–3, 219

local lymph node assay (LLNA) 81, 129, 222

local tolerance 128–30

bovine corneal opacity and permeability test (BCOP) 128, 189

clinical phase studies 222–3

hen chorio-allantoic membrane test (HET-CAM) 128–9, 189
INDEX

397

in vivo vascular tolerance assay 129–30
local lymph node assay (LLNA) 129
phototoxicity assay 129, 222–3
pre-clinical phase studies 189–90
longitudinal clinical trials 148
Lower Limit Of Quantification (LLOQ) 117
lyophilisation 96
machinery 62
magnetic resonance imaging (MRI) 143–4
functional MRI (fMRI) 144
magnetic resonance spectroscopy (MRS) 144
management risks 77
manufacturing process development 203–6, 210
market access 327–8, 363
marketing. see pharmaceutical marketing
Marketing Authorisation (MA) 44, 316–28
application for 44, 51, 55, 311
available evidence evaluation 311–13
benefit-risk assessment 314–15
overall quality, efficacy and safety assessment 313–14
preparation of MA application file 315–16
worldwide MA application strategy 315
European procedures 318–23, 325
centralised procedure 318–20, 319
decentralised procedure 322, 322–3
mutual recognition procedure 320–321, 321
national procedures 323
granting of 325–6
special procedures 323–5
updates 346–7
US procedures 316–18, 317, 324–5
marketing research 375–6
market research 374–5
mass-balance studies 110–111, 111, 218
mass spectrometry 101–2
accelerator (AMS) 192
MALDI-MS 116–17
secondary ion (SIMS) 116–17
tandem (MS/MS) 102, 102, 117
matrix-assisted laser desorption ionisation (MALDI) 101
mass spectrometry (MALDI-MS) 116–17
Maximum Expected Environmental Concentration (MEEC) 295
Maximum Recommended Safe Starting Dose (MRSD) calculation 199–200
Maximum Tolerated Dose (MTD) 131, 233, 242
carcinogenicity studies 286
mechanistic toxicology 226, 331–2
medical congresses 379–80
medical journals, advertising in 378
medical need programmes 327
melanin binding 217
melting point determination 105
meta-analyses 149, 161
metabolism 31, 107, 111–15, 218–19
First-In-Human (FIH) study 237
human metabolism study 218–19
in vitro 32, 113, 182–3
liver enzyme inhibition and induction 115, 182–3, 219
metallic impurities 266
micellar systems 98
microbial inhibition test 295
microbial purity
active ingredient 267–9, 269
drug product 277–9, 278
microdose studies 190–192, 191
microemulsions 99
micronucleus assay 127–8, 188
Minimal-Anticipated-Biological-Effects-Level (MABEL) 200
misconduct 80
modified Irwin’s test 124, 125, 185
molecular drug design 15–16
mouse lymphoma assay 127, 188
Multi-Criteria Decision Analysis (MCDA) 315
Multiple Ascending Dose (MAD) study 240–243
drug administration 241–2
participants 240
pharmacodynamics 243
pharmacokinetics 242–3
safety and tolerability 242
setting 240
study design 240–241
multiple reaction monitoring (MRM) 102
nanosuspensions 98
national drug bulletins 382
national drug formularies 382
Net Present Value (NPV) 9
network meta-analysis 161
neurotoxicology 138, 225–6
New Drug Application (NDA) 46, 51, 55–7, 316–18
new drug development. see drug development
new indications 342
nonclinical development 31–2, 106–38, 180–190
clinical phase 215–26
Environmental Risk Assessment (ERA) 290–297
post-approval studies 329–32
nonclinical development (continued)
pre-approval studies 282–97
pre-clinical phase 180–190
safety pharmacology 119–24, 183–6
toxicology 125–38, 186–90, 219–26, 283–90
non-inferiority trials 153–4, 154, 304
non-interventional clinical trials 148
No-Observed-Adverse-Effect-Level (NOAEL) 126, 131, 187
embryo-fetal development studies 135
fertility studies 133
Human Equivalent Dose (HED) derivation 198, 199
juvenile development studies 135
pre- and post-natal development studies 135
No-Observed-Effect-Concentration (NOEC) 293
nuclear magnetic resonance spectrometry (NMR) 102–3, 103
Number Needed to Harm (NNH) 163
Number Needed to Treat (NNT) 163
Nuremberg Code 83
observational studies 149, 154–7
Odds Ratio (OR) 162
Office of Orphan Products Development (OOPD) 353
Office of Prescription Drug Promotion (OPDP) 381
off-label use 342
Operating Manuals (OPM) 70
organisational risks 77
Organisation for Economic Co-operation and Development (OECD) 47
organogenesis 224
Orphan Drug Act, US 353
orphan drug development 351–3, 354
overage 213
packaging materials 213
container closure system 213–14
paediatric drug development 354–6
dose selection 355–6
clinical-trial-based 356
PK-based 355–6
legislation 357
Paediatric Investigation Plan (PIP) 55, 316, 326, 355
paracetamol metabolism 114, 114–15
parallel artificial membrane permeation assay (PAMPA) 19, 107, 182
parallel group study design 150, 151
First-In-Human (FIH) study 233, 233
Multiple Ascending Dose (MAD) study 240, 241
parenteral administration 21
parenteral formulations 96
parenteral tolerance 190
particle size 266, 267
partition coefficient 93–4
Patented Medicine Prices Review Board (PMPRB), Canada 364
Patient-Centered Outcomes Research Institute (PCORI) 337–8
patient organisations 380
payments to clinical trial participants 87, 228
Pediatric Research Equity Act (PREA), US 356
Periodic Benefit-Risk Evaluation Reports (PBRER) 345–6
per protocol (PP) study set 159
personalised treatment 344–5
personnel 61–2, 64
P-glycoprotein (P-gp) 217
pH adjustment 97
pharmaceutical market 370–372, 371
market segmentation 376
trends 371–2
pharmaceutical marketing 370–382
channels and tools 378–80
institutional providers 380
Key Opinion Leaders (KOL) 380
patients 380
prescribers 378–80
drug promotion regulation 381–2
general principles 372–4
marketing plan 381
marketing research 375–6
marketing strategy 376–8
co-marketing 377–8
co-promotion 377–8
disease management 378
market segmentation 376
product positioning 376–7
targeting 377
market research 374–5
Pharmaceutical Price Regulation Scheme (PPRS), UK 364
pharmacodynamics 243–4
First-In-Human (FIH) study 238–9
Multiple Ascending Dose (MAD) study 243
pharmacokinetic/pharmacodynamic (PK/PD) analysis 139–40
pharmacoeconomic evaluation 365–9
cost analysis 366
Cost-Benefit Analysis (CBA) 367
Cost-Effectiveness Analysis (CEA) 366–8, 368
Cost-Minimisation Analysis (CMA) 366
Cost-Utility Analysis (CUA) 366–7
pharmacokinetics 31, 107–19
absorption in vitro 107–8
clinical phase studies 216–19, 243
First-In-Human (FIH) study 237–8
Multiple Ascending Dose (MAD) study 242–3
phase 2a studies 248
excretion 110–111
in vivo 32
metabolism 111–15, 182–3, 218–19
modelling 118, 118–19
pharmacokinetic/pharmacodynamic (PK/PD) analysis 139–40
plasma kinetics 108–10, 109, 110, 216–17
post-approval studies 329–30
pre-approval studies 282–3
pre-clinical phase studies 180–183
tissue distribution 115–17, 217–18
pharmacometrics 139–40
pharmacovigilance (PV) 338–42
additional activities 340–342
recent initiatives 341–2
routine activities 339
Pharmacovigilance Risk Assessment Committee (PRAC) 341
phase 2a studies 226–7, 245–50
conduct 246
evaluation criteria 248
formulation for 209, 209–10
objectives 245–6
participants 246
pharmacokinetics 248
Proof-of-Concept (PoC) approaches 249–50
research tools 247
setting 246
study design 247–8
phase 2b studies 254, 280, 297–9
end-of-phase 2 meeting 299–300
formulation for 256–7
study design 298
see also pre-approval development
phase 0 studies 190–192, 191
phase 1 studies 226–45
conduct 230–231
exclusion criteria 230
formulation for 175–6, 209
go/no-go decision 245
integrated studies 244, 245
phase 1a (single-dose trials) 231–40
First-In-Human (FIH) study 231–9
phase 1b (repeated-dose trials) 240–244
Multiple Ascending Dose (MAD) study 240–243
recruitment 229–30
setting 228–9
phase 3 studies 254, 280, 300–311
absolute efficacy and safety 301–3
clinical safety studies 305–10
formulation for 256, 256–7
relative efficacy and safety 303–5
strategic choices 301
see also pre-approval development
phase 4 studies 333–4
phenotypic screening 14
photostability studies 212
phototoxicity assay 129, 222–3
physiologically-based pharmacokinetic models (PBPK) 118, 118, 139
PK/PD analysis 139–40
pK value determination 92
placebo use 85–6
placental transfer 217
plant transfer 43–4
plaque-forming cell (PFC) assay 137
plasma kinetics 108–10, 109, 110, 216–17
First-In-Human (FIH) study 237
polymorphic modifications 92–3, 266–7, 272–3
specification 266–7, 268, 272–4
polyoxyl castor oil 98
polysorbates 98
population pharmacokinetic analysis 139
portfolio 8
portfolio team 10
positron emission tomography (PET) 144–5, 192
post-approval development 328–47
chemical and pharmaceutical development 328
clinical development 333–45
Comparative Effectiveness Research (CER) 336–8
effectiveness vs. efficacy 334–6
new developments 342–5
pharmacovigilance 338–42
phase 4 studies 333–4
integration and decision making 345–7
nonclinical development 329–32
pharmacokinetics 329–30
toxicology 330–332
Post-Authorisation Safety Studies (PASS) 340
Post-Marketing Surveillance (PMS) 338
post-natal development studies 135, 136, 224–5, 288
potassium channel tests 18–20, 119–21, J20, 185
pre-approval development 254–316
chemical and pharmaceutical development 254–81
active ingredient 255–6
changes during development 279–81
drug product 256–7
final quality specifications 257–79
final stability testing 279
clinical development 297–311
**INDEX**

- **pre-approval development (continued)**
  - end-of-phase 2 meeting 299–300
  - phase 2b studies 297–9
  - phase 3 studies 300–311
  - integration and decision making 311–16
  - nonclinical development 282–97
  - Environmental Risk Assessment (ERA) 290–297
  - pharmacokinetics 282–3
  - toxicology 283–90
- **Pre-Approval Inspections (PAI)** 73
- **Pre-clinical phase of development** 170–200
  - chemical and pharmaceutical development 170–180
  - analytical development 176
  - early quality specifications 177–80
  - formulation development 171–6
  - new synthesis method 170–171
  - clinical development 190–196
  - clinical phase planning 193–6
  - phase 0 studies 190–192
  - integration and decision making 196–200
  - nonclinical development 180–190
  - pharmacokinetics 180–183
  - safety pharmacology 183–6
  - toxicology 186–90
- **Predicted Environmental Concentration (PEC)** 291, 292, 294
- **Predicted No-Effect Concentration (PNEC)** 292, 293
- **pre-formulation research** 171–2
- **pre-natal development studies** 135, 136, 224–5, 288
- **prescribers, marketing to** 378–80
- **Prescribing Information (PI)** 313, 315, 325
- **Prescription-Event Monitoring (PEM)** 340
- **Preservative Efficacy Test (PET)** 278, 279
- **Priority Review** 324
- **PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)** 163
- **Progressive drug risk assessment** 306–8
- **prodrugs** 96, 219
- **production procedures** 62
- **product positioning** 376–7
- **product quality review** 61
- **product recalls** 62–3
- **project risk management** 75–9
  - analysis of risk 78–9
  - First-In-Human (FIH) study 195–6
  - nature of risk 75–6
  - types of risk 77
- **Proof-of-Concept (PoC)** 226–7, 246, 249–50
- **Proof-of-Confidence (PoC)** 250
- **Proof-of-Mechanism (PoM)** 238, 244
- **Proof-of-Principle (PoP)** 238, 244
- **prospective clinical trials** 148
- **protein binding** 115–16
- **protein-ligand interaction** 16, 16
- **purification processes** 256
- **Purkinje fibre assay** 121, 122, 185
- **QT interval prolongation** 184–5, 244, 306–8, 332
- **qualification study** 260–261
- **Quality-Adjusted Life Years (QALYs)** 366–8
- **quality determination** 99–106
  - chromatography 103–5
  - melting point 105
  - spectrometry 100–103
  - stereochemical purity 106, 208
- **quality management** 58–75
  - audits 72
  - general principles 58–9, 59
  - good practices 59–70, 60
    - Good Clinical Practices (GCP) 66–70
    - Good Laboratory Practices (GLP) 63–6
    - Good Manufacturing Practices (GMP) 60–63
    - inspections 72–3
    - overall quality assessment 313
    - Quality Assurance (QA) 61, 64, 72
    - Quality by Design (QbD) approach 74, 75, 214–15
    - Quality Control (QC) 61, 71–2
    - Quality Risk Management (QRM) 73–5
    - Standard Operating Procedures (SOP) 70–71
    - Quality Management System (QMS) 59, 60
- **quality specifications**
  - active ingredient 178–9, 257–69
    - Critical Quality Attributes (CQAs) 206
    - impurity profiling and reporting 257–64
    - microbial purity 267–9, 269
    - particle size 266, 267
    - polymorphic modifications 266–7, 268, 272–3, 274
    - residual solvent 265–6
    - drug product 179–80, 181, 270–279
    - degradation 270–272, 271
    - in vitro dissolution 273–7, 275, 276, 277
    - microbial purity 277–9, 278
    - polymorphism 272–3, 274
    - early development 177–80
    - pre-approval development 257–79
- **Quality Target Product Profile (QTPP)** 214
- **quantitative whole-body autoradiography (QWBA)** 116
- **Randomised Controlled Trial (RCT)** 149–54
- **blinding** 150
randomisation 150
study designs 150–153
types of comparison 153–4
types of control 149
see also clinical trials
ranolazine 308
rare diseases 351–2
rational use of medicines 383–4
recalls 62–3
reference items 65
registration batches 255
registration procedure. see marketing
authorisation (MA)
regulation 44–58
animal studies 81–2
authorities and organisations 45–8, 49
drug promotion 381–2
legislation and guidelines 44–5
processes and documents 48–58, 50, 51
reimbursement. see drug reimbursement
Relative Effectiveness Assessment (REA) 336
Relative Risk (RR) 162
renal insufficiency 310
repeated-dose toxicology 130–132, 131, 132
clinical phase studies 219–21
pre-approval studies 283–4
pre-clinical phase studies 186–7, 197–8
reporting
Adverse Drug Reactions (ADRs) 339
degradants 271–2, 272, 273
environmental risk 294, 296–7
impurities 262–4, 264
study results 65, 162–3
reprocess procedures 255
reproductive cycle 223, 223
reproductive toxicology 132–5, 223–5
embryo-fetal development 133–5, 134, 224, 288
fertility 133, 134, 224, 288
juvenile development 135, 137, 288–90
pre- and post-natal development 135, 136, 224–5, 288
 Request for a Special Protocol Assessment 51
residual solvent 265–6
respiratory safety 124
retrospective clinical trials 148
rework processes 255–6
risk assessment
drug candidate 193
First-In-Human study 195–6
see also safety pharmacology; toxicity
Risk Difference (RD) 162
risk management
First-In-Human (FIH) study 196
Quality Risk Management (QRM) 73–5
Risk Evaluation and Mitigation Strategy
(REMS) 316, 326, 338
Risk Management Plan (RMP) 314, 316, 326, 338
regular review of 346
see also pharmacovigilance (PV); project risk
management; safety pharmacology
Risk Ratio (RR) 162
risk score 78, 78–9
risk-sharing schemes 369
rosiglitazone 308
safe starting dose calculation 199–200, 235
safety pharmacology 119–24, 183–6, 197
cardiovascular safety 119–24, 184–6, 197, 244
phase 3 studies 306–10
CNS safety 124
First-In-Human (FIH) study 236–7
multiple ascending dose (MAD) study 242
overall safety assessment 314
phase 2a studies 248
respiratory safety 124
see also pharmacovigilance (PV); risk
management; toxicology
sales representatives 378
Salmonella typhimurium 126
scientific research integrity 79–80
screen failures 302
screening 18, 20
stability 211
secondary ion mass spectrometry
(SIMS) 116–17
selection failures 302
self-inspection 63
self-(micro)emulsifying drug delivery systems
(SEDDS/SMEDDS) 99
sequential cohort study design 233–4, 234
Serious Adverse Drug Reaction (SADR) 236
Serious Adverse Event (SAE) 236
sewage treatment plant (STP) studies 292–3, 294
show stoppers 79
SimpleTreat model 294
Single Ascending Dose (SAD) study 233, 231, 233
study design 233, 233–4, 234
single-photon emission computed tomography
(SPECT) 144–5
skin
primary irritation 222
sensitisation 222
see also local tolerance
S9-mix 126–7
societal value 9
solid dispersions 99
solubility 171–3
testing 92
solvents 265–6
sonic spray ionisation (SSI) 101
specified impurities 261
spectrometry 100–103
fluorometry 100
IR spectrometry 100, 101
mass spectrometry 101–2
nuclear magnetic resonance spectrometry (NMR) 102–3, 103
UV and visible spectrometry 100
sponsor 68
stability testing 94, 210–213
active ingredient 211, 211–12
drug product 212–13
clinical trials 279
screening stability 211
stress stability 211
see also degradation
Standard Operating Procedures (SOP) 70–71
statistical analysis issues 159–60
stereochemical purity determination 106, 208
enantiomer specification setting 269, 270
stress testing 211
STROBE (Strengthening The Reporting of OBservational studies in Epidemiology) 163
study endpoints 157–9, 302
composite endpoints 158
surrogate endpoints 159
study performance 65
Summary of Product Characteristics (SmPC) 313, 315, 325
superiority trials 153
surface characteristics 94
surface water studies 293, 293–4
surfactant systems 98
surrogate endpoints 159
Swedish Institute for Drug Informatics (SIDI) 382
SWOT analysis 375, 375
systematic reviews 149
tables 95–6
tailored treatment 344–5
targeting 377
team risks 77
technical risks 77
teratogenicity see embryo-fetal development studies
test facilities 64
test items 65
test systems 64–5
therapeutic area/portfolio risk 7
thin-film hydration 99
through QT (TQT) study 244, 306–8
borderline results 307, 307
Threshold of Toxicological Concern (TTC) 221–2, 265, 284
thyroid follicular adenoma, rat 287
time-of-flight (TOF) principle 101
tissue distribution 115–17, 183, 217–18
bioanalysis 117
protein binding 115–16
whole-body distribution 116–17, 183
tolerability
First-In-Human (FIH) study 236–7
Multiple Ascending Dose (MAD) study 242
topical formulations 96–7
tox formulations 175
toxicokinetics 31, 107, 182, 216
post-approval studies 329–30
pre-approval studies 282–3
toxicology 31, 32, 125–38, 216
acute 125–6, 186
carcinogenicity 136, 138, 221, 284–8, 330–331
clinical phase studies 219–26
genotoxicology see genotoxicity
immunotoxicology 136–8, 225
juvenile toxicology 288–90, 329, 331
local tolerance 128–30, 189–90, 222–3
mechanistic 226, 331–2
minimum duration of studies 187
neurotoxicology 138, 225–6
post-approval studies 330–332
pre-approval studies 283–97
pre-clinical phase studies 186–90
reproductive toxicology 132–5, 223–5, 288
see also repeated-dose toxicology
see also safety pharmacology
transparency 80–81
transporter proteins 217–18, 218
trial models 140
trifluorothymidine (TFT) 127
tubular carcinoma of the kidney, rat 287
ultrasonography (US) 145
ultraviolet (UV) spectrometry 100
uncontrolled clinical trials 148
Unified Methodologies for Benefit-Risk Assessment (UMBRA) 314
Unique Selling Proposition (USP) 374
unmet medical need 3, 329
Upper Limit Of Quantification (ULOQ) 117
US Pharmacopoeia 48
validation 255
analytical methods 257, 258–9
validity 160
vascular tolerance assay 129–30
whole-body autoradiography (WBA) 116, 183
withdrawal from the market 9–10